{
  "id": 471486,
  "title": "STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more",
  "url": "https://urgent.news/2026/08/10/stat-pharmalittle-were-reading-about-a-sanofi-drug-shortage-a-jazz",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T13:24:23.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/08/10/sanofi-drug-shortage-jazz-pharma-deal/"
  },
  "original_language": "en",
  "account": "Good morning, everyone, and welcome back to another busy workweek. The weekend may have provided a well-deserved break, but now the usual cycle of meetings and deadlines has returned. To help you get through, we're offering a special blend of honeybush vanilla turmeric. Feel free to join us, as there are important updates to share.\n\nFirstly, Sanofi is currently facing a shortage of two medicines used to treat Pompe disease. This issue arose following warnings from the U.S. Food and Drug Administration about manufacturing problems at the company's Irish facility. Myozyme, an older standard of care, and Nexviazyme, a newer treatment, are experiencing a bottleneck in the final manufacturing phase and quality control issues at the Waterford plant. The drugmaker has informed patient groups and physicians in both the U.S. and Europe about the dwindling supplies, per STAT.\n\nIn other pharmaceutical news, Jazz Pharmaceuticals has agreed to acquire Actio Biosciences in a deal worth up to $1.32 billion. This acquisition will add an experimental treatment for KCNT1-related epilepsy, a rare inherited form of epilepsy with no approved therapies. The experimental treatment, called ABS-1230, has shown promise in early studies of children, reducing seizures and improving developmental problems. The company is evaluating ABS-1230 in a study aimed at supporting a U.S. approval application, as reported by Reuters.",
  "summary": "Sanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issues",
  "key_points": [
    "Sanofi faces drug shortage for Pompe disease treatments Myozyme and Nexviazyme",
    "Jazz Pharma acquires Actio Biosciences for $1.32 billion",
    "Jazz's ABS-1230 shows promise in treating KCNT1-related epilepsy"
  ],
  "editors_take": "Sanofi's manufacturing issues at its Irish facility mean patients with Pompe disease face limited access to crucial treatments, while Jazz Pharmaceuticals expands its rare disease portfolio with the acquisition of Actio Biosciences.",
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "BioPharma Dive",
        "title": "Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal",
        "url": "https://urgent.news/2026/08/10/jazz-to-buy-rare-epilepsy-drugmaker-in-potentially-1-3b-deal",
        "published": "2026-08-10T15:36:00.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more",
        "url": "https://urgent.news/2026/08/11/stat-pharmalittle-were-reading-about-an-fda-rejection-340b-court",
        "published": "2026-08-11T13:27:20.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}